(Q53568958)

15 May 2018

title

Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. (English)

1 reference

15 May 2018

author name string

Judy W M Cheng

1

1 reference

15 May 2018

Hisham A Badreldin

2

1 reference

15 May 2018

Dhiren K Patel

3

1 reference

15 May 2018

Snehal H Bhatt

4

1 reference

15 May 2018

language of work or name

English

0 references

publication date

15 February 2017

1 reference

15 May 2018

Current Medical Research and Opinion

published in

1 reference

15 May 2018

volume

33

1 reference

15 May 2018

issue

6

1 reference

15 May 2018

page(s)

985-992

1 reference

15 May 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

cites work

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

The effects of improved glycemic control on complications in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Results of a reevaluation of cardiovascular outcomes in the RECORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Impairment of myocardial protection in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

8. Pharmacologic Approaches to Glycemic Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03007995.2017.1284052

10.1080/03007995.2017.1284052

21 January 2018

Identifiers

DOI

1 reference

15 May 2018

release_ip3eg67mpfgvzlizv5afo2tno4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ip3eg67mpfgvzlizv5afo2tno4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

28097882

1 reference

15 May 2018